Liraglutide Treatment May Affect Renin and Aldosterone Release
| العنوان: | Liraglutide Treatment May Affect Renin and Aldosterone Release |
|---|---|
| المؤلفون: | Eero Vasar, Vallo Volke, Tuuli Sedman, Keiu Heinla |
| المصدر: | Hormone and Metabolic Research. 49:5-9 |
| بيانات النشر: | Georg Thieme Verlag KG, 2016. |
| سنة النشر: | 2016 |
| مصطلحات موضوعية: | Adult, Male, Agonist, Hypothalamo-Hypophyseal System, medicine.medical_specialty, Adolescent, medicine.drug_class, Endocrinology, Diabetes and Metabolism, Clinical Biochemistry, Pituitary-Adrenal System, 030209 endocrinology & metabolism, 030204 cardiovascular system & hematology, Pharmacology, Biochemistry, Renin-Angiotensin System, Young Adult, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Endocrinology, Glucagon-Like Peptide 1, Internal medicine, Renin, Renin–angiotensin system, medicine, Humans, Hypoglycemic Agents, Receptor, Aldosterone, Glucose tolerance test, medicine.diagnostic_test, business.industry, Liraglutide, Sodium, Biochemistry (medical), General Medicine, Middle Aged, Healthy Volunteers, chemistry, Mineralocorticoid, Potassium, Female, business, Glucocorticoid, medicine.drug |
| الوصف: | Nowadays, GLP-1 receptor agonists are widely used as effective and safe antidiabetic medications. In addition to glucose-dependent insulin secretion, their effects reach beyond glucose control. Previously, it has been shown that acute administration of GLP-1 receptor agonists increases circulating glucocorticoid and mineralocorticoid levels in both humans and rodents. So far, no studies have reported the effects of chronic administration of GLP-1 receptor agonists on the hypothalamic-pituitary-adrenal axis in humans. The aim of the current study was to examine the effects of acute and chronic treatment with the GLP-1 receptor agonist liraglutide on adrenal function in humans. Ten healthy volunteers were recruited into a single group open-label clinical trial. Each participant was tested for baseline levels, and after acute and chronic treatment with 0.6 mg liraglutide daily. A graded glucose infusion test was performed 3 times. We found that aldosterone tended to be suppressed (albeit not statistically different) after acute administration of liraglutide, and increased after chronic dosing; the difference was statistically significant when compared between acute and chronic dosing. Changes in aldosterone levels followed the changes in renin concentrations and the aldosterone-to-renin ratio remained stable. No statistically significant differences were observed in ACTH or cortisol levels. In conclusion, we have shown that a low dose of GLP-1 receptor agonist may interfere with renin and aldosterone release. Further studies in a larger patient sample and with higher doses of GLP-1 receptor agonists are warranted to corroborate this finding. The study protocol was registered at clinical.trials.gov (NCT02089256) and EU Clinical Trial Register (2014-000238-43). |
| تدمد: | 1439-4286 0018-5043 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c9e395cd4484c3bf634aa63b0c427c90Test https://doi.org/10.1055/s-0042-109065Test |
| رقم الانضمام: | edsair.doi.dedup.....c9e395cd4484c3bf634aa63b0c427c90 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 14394286 00185043 |
|---|